Rowinski Group LLC works with companies who are financing, developing, and selling medical devices, digital health platforms and, diagnostics for the U.S healthcare market. Since the founding of Rowinski Group in 2004, we have been retained by privately held and publicly traded companies based on five continents: North America, Australia, Asia, Europe and the Middle East.
Our priority is to help our companies to establish and to build their U.S. market share, regardless of their location and stage of development. We work with companies to secure CPT, HCPCS and ICD10 codes and commercial insurance, Medicaid and Medicare coverage and reimbursement for the medical technology under development for or being sold in the U.S market.
In the absence of commercial insurance, Medicaid and Medicare coverage and reimbursement for a company’s medical technology, we will investigate if alternative monetization pathways exist to traditional reimbursement. Reimbursement is the most well known and ideal monetization pathway. However for some medical technologies traditional reimbursement may not be the exclusive monetization pathway.
Another way we work with companies is using healthcare payer and reimbursement data to solve complex operating problems. We’ve used payer and reimbursement data to help our companies; 1) respond to questions from the U.S. FDA, 2) determine the geographic placement of their sales force and clinical trial sites, 3) build marketing and sales revenue and unit models and, 4) ascertain the impact of regulatory Indications-for-Use and Claims on a medical technology’s pricing strategy and coding and reimbursement options.
The applications and possibilities of using healthcare payer and reimbursement data to help solve coding, reimbursement, regulatory, marketing and sales issues is now affordable, accessible and usable.
